News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


PHARMAC steps up to help meet Government cancer treatment g

7 December 2012

Media release

PHARMAC steps up to help meet Government cancer treatment goal

Recent decisions by PHARMAC will have a positive effect on cancer treatment in New Zealand.

PHARMAC has removed the Special Authority funding requirements from seven cancer treatments, and from the diabetes treatment pioglitazone. Special Authorities define the clinical criteria patients must meet to receive some funded medicines. Clinicians must complete a Special Authority application and receive approval before prescribing in order for the patient to receive the funded medicine.

PHARMAC’s medical director Dr Peter Moodie, says the lifting of these funding restrictions is a positive step.

“Removing the Special Authorities from these cancer treatments will significantly reduce administrative demands on the hospital oncologists and haematologists who routinely prescribe these drugs,” says Dr Moodie.

“In addition, one of the medicines being de-restricted is capecitabine, a tablet which can be used in place of 5-flourouracil, a chemotherapy infusion that patients need to receive in hospitals or special treatment centres. Patients prescribed capecitabine will have a more convenient treatment option which they can take at home and this is particularly helpful for rural people and reduces their costs of receiving treatment.

“Removing the Special Authority restrictions will also free up hospital resources that can be used to treat more patients overall, which will help DHBs achieve the Government health priority to reduce cancer treatment waiting times.”

The medicines having Special Authority funding requirements removed are:

o Anagrelide hydrochloride – primarily used to treat thrombothycaemia (overproduction of platelets)

o Gemcitabine hydrochloride - used to treat a variety of cancers including bladder, breast, pancreas, lymphoma, lung and ovarian cancer.

o Irinotecan - primarily used to treat bowel and pancreatic cancer.

o Oxaliplatin - primarily used to treat bowel, pancreas and stomach cancer.

o Vinorelbine - primarily used to treat lymphoma, lung and breast cancer

o Capecitabine – primarily used to treat breast, bowel and stomach cancer

o Octreotide – primarily used in cancer for endocrine tumours and for palliation of symptoms in patients with malignant bowel obstruction.

Overall, removing the Special Authorities from these medicines will reduce the number of applications by about 4000 per year.

The Special Authorities were removed from these treatments from 1 December 2012 meaning that they are now fully funded by DHBs for any cancer patients. In addition, capecitabine is funded for any patient in the community when prescribed by a specialist.

Dr Moodie says that making access easier, such as by removing Special Authorities, usually results in more patients being prescribed the treatment.

“Effectively, this means we are giving doctors treating cancer greater discretion in how they choose to treat their patients, in the knowledge that it will be funded for them.”

Pioglitazone is a treatment that increases the body’s sensitivity to insulin, and is mainly used to treat Type 2 diabetes.

As with the cancer treatments, the Special Authority on pioglitazone was removed from 1 December.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis: Never Too Old To Rock & Roll - Jethro Tull

As Greil Marcus recently observed in an NYRB review of Robbie Robertson's autobiographical Testimony, in rock and roll there is always an origin story. In the case of Jethro Tull founder Ian Anderson, he claims to have been influenced by his father's big band and jazz record collections and the emergence of rock music in the 1950s, but became disenchanted with the "show biz" style of early US stars like Elvis Presley... More>>

October: Alice Cooper Returns To NZ

It was March 1977 when Alice Cooper undertook his first ever concert tour of New Zealand – and broke attendance records. 40 years on and this revered entertainer continues to surprise and exude danger at every turn, thrilling audiences globally! More>>

ALSO:

Howard Davis Review: The Contemporary Relevance Of Denial

Denial has all the hallmarks of a riveting courtroom drama. Based on a 1996 British libel case that author David Irving brought against Lipstadt, the movie has been criticized as flat and stagey, but it nonetheless conveys a visceral clarity of vision and sense of overwhelming urgency. More>>

Obituary: John Clarke Dies Aged 68

Andrew Little: “I grew up with Fred Dagg and I am devastated by John Clarke’s death. He taught us to laugh at ourselves and more importantly laugh at our politicians.” More>>

ALSO:

Howard Davis: Colin McCahon's 'on Going Out With The Tide'

Curated by Wystan Curnow and Robert Leonard, On Going Out with the Tide features major works that have been assembled from public and private collections across New Zealand and Australia. It focusses on McCahon’s evolving engagement with Māori subjects and themes, ranging from early treatments of koru imagery to later history paintings which refer to Māori prophets and investigate land-rights issues. More>>

Howard Davis: Rodger Fox Gets Out The Funk

By now a living New Zealand legend, band leader and trombonist Rodger Fox has performed with some of the biggest names in the jazz business, including Louie Bellson, Bill Reichenbach, Chuck Findley, Randy Crawford, Bobby Shew, Lanny Morgan, Bruce Paulson, Diane Schuur, Arturo Sandoval, David Clayton-Thomas, and Joe Williams, to name only a few. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news